ArticleJournal of clinical research in pediatric endocrinology2026
Real-World Efficacy of Weekly Somatrogon on Growth and Bone Health in Pediatric Growth Hormone Deficiency: A 12-Month Retrospective Cohort Study
Article in Journal of clinical research in pediatric endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Growth hormone deficiency (GHD) in children results in short stature and impaired bone health. While daily growth hormone (GH) injections are effective, they are associated with adherence challenges. Somatrogon, a long-acting, recombinant human GH (rhGH), allows weekly administration, potentially improving treatment compliance. Methods: This retrospective cohort study included prepubertal children with GHD treated with weekly Somatrogon at Al Jalila Children’s Hospital, Dubai. Diagnosis was based on clinical, biochemical, and radiological criteria, including height standard deviation score (SDS) <-2.0, subnormal growth velocity, and subnormal peak GH in one stimulation test (<10 ng/mL), supported by low IGF-1 and/or abnormal cranial magnetic resonance imaging. Growth outcomes and bone health indices were assessed over 12 months using auxology, insulin-like growth factor 1 (IGF-1) levels, and BoneXpert-derived bone health index (BHI) SDS and Metacarpal Index (MCI) SDS. Results: The study cohort consisted of 39 children with GHD. After 12 months of therapy, mean height SDS improved significantly from -2.16±0.80 to -1.65±0.71 (p<0.001). IGF-1 SDS rose from -1.38±1.02 to 0.88±1.57 (p<0.001). Adult predicted height and BHI SDS also improved significantly (p=0.005 and p<0.001, respectively). No significant changes were observed in bone age SDS or MCI SDS. Conclusion: Weekly Somatrogon significantly improved linear growth, IGF-1 levels, and measures of cortical bone health without advancing bone age in children with GHD. These findings support the efficacy of this form of long-acting GH therapy and its potential to optimize growth and skeletal outcomes in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.